We retrospectively collected information from 273 patients who underwent IVF/ICSI with fresh embryo transfer following an endometrial curettage in the proliferative-phase from January 2020 to May 2022 in the Reproductive Hospital of Jiangxi University of Traditional Chinese Medicine. These patients had no or only 1 previously failed cycle. Patients with uterine abnormalities, endometriosis, intrauterine adhesions (moderate-severe), adenomyosis, uterine mediastina and ovarian tumors, untreated hydrosalpinx, or abnormal uterine bleeding were excluded. All data of patients on demographics, baseline values, and pregnancy outcomes were available. We obtained ethical approval from the Medical Ethics Committee of Nanchang Reproductive Hospital (the Reproductive Hospital of Jiangxi University of Traditional Chinese Medicine) (approval number 2022.005).